Literature DB >> 17196256

Fetal growth restriction is associated with reduced FasL expression by decidual cells.

Irina P Eide1, Christina V Isaksen, Kjell A Salvesen, Mette Langaas, Clara-Cecilie Günther, Ann-Charlotte Iversen, Rigmor Austgulen.   

Abstract

The Fas-Fas ligand (FasL) system contributes to immune tolerance at the feto-maternal site and has been ascribed a role in implantation and placental development by regulating trophoblast invasion and spiral artery remodelling. In the present study, we have examined FasL expression in decidual tissue from pregnancies with impaired placental development. Women with pre-eclampsia (PE) and/or fetal growth restriction (FGR) were enrolled as cases (n=33), and women with normal pregnancies were used as controls (n=27). Decidua basalis tissue was obtained by vacuum suction of the placental bed after delivery. FasL expression by extravillous trophoblasts (EVTs) and decidual cells (DeCs), together with EVT apoptosis, were assessed by immunohistochemistry. Levels of soluble FasL in maternal serum and apoptosis-related gene expression in decidual tissue were determined. The proportion of FasL-expressing DeCs was high in controls (72.0+/-10.2%), with a significant reduction among cases (58.1+/-19.7%; p=0.002), especially in those with FGR (54.3+/-19.9%; p<0.001). EVTs had a lower proportion of FasL expression than DeCs, with a less pronounced reduction in cases compared to controls (10.9+/-3.9 and 8.3+/-4.0%, respectively; p=0.02). Decidual FasL expression correlated with placental growth. The EVT apoptosis rate did not differ between cases and controls (1.1+/-1.9 and 1.1+/-1.3%, respectively). These findings indicate a reduction of immune privilege in decidua of PE/FGR pregnancies by reduced FasL expression and that DeCs may have a central role in the Fas-FasL-based feto-maternal immune balance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196256     DOI: 10.1016/j.jri.2006.11.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  4 in total

1.  FAS and FAS-L genotype and expression in patients with recurrent pregnancy loss.

Authors:  Priscilla Chamelete Andrade Banzato; Silvia Daher; Evelyn Traina; Maria Regina Torloni; Bárbara Yasmin Gueuvoghlanian-Silva; Renata Fiorini Puccini; Karen Priscilla Tezotto Pendeloski; Rosiane Mattar
Journal:  Reprod Sci       Date:  2013-02-18       Impact factor: 3.060

2.  Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome.

Authors:  K John; S Wielgosz; K Schulze-Osthoff; H Bantel; R Hass
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

Review 3.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 4.  Innate Lymphoid Cells at the Maternal-Fetal Interface in Human Pregnancy.

Authors:  Rui-Qi Chang; Wen-Jie Zhou; Da-Jin Li; Ming-Qing Li
Journal:  Int J Biol Sci       Date:  2020-01-30       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.